Search Results for: 124

Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program

— Novel Oral Biologic Designed to Protect Patients from C. difficile Infection Associated with Systemic Antibiotics — ROCKVILLE, Md., Nov. 12, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that the Company has entered into an agreement with Prev AbR […]

Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program Read More »

Synthetic Biologics Reports Second Quarter 2012 Financial Results

— Addition of Monoclonal Antibodies for Infectious Diseases Emphasizes Focus on Synthetic Biologics — ANN ARBOR, Mich., Aug. 14, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for unmet medical needs, today reported financial results for the three and six months ended June 30, 2012 and

Synthetic Biologics Reports Second Quarter 2012 Financial Results Read More »